SUMMARY One hundred and three outpatients with endoscopically diagnosed duodenal ulcer were randomly allocated to treatment with either cimetidine 200 mg tds and 400 mg nocte, or ranitidine 150 mg bd for four weeks. The endoscopists were not aware of the treatment and took no part in the clinical management. On completion of treatment ulcers had healed in 43 of 51 (84%) patients given cimetidine and in 40 of 52 (77 %) patients given ranitidine. There were no serious unwanted effects in either treatment group. The results show no significant difference between healing rates after four weeks of standard cimetidine therapy or ranitidine 150 mg bd.
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Cimetidine, the first histamine H2-receptor antagonist to be widely available, is accepted as effective therapy for duodenal ulcer.1 Ranitidine (Fig. 1) is a new H2-receptor antagonist with a different chemical structure and greater potency than cimetidine.2-8 We have previously shown that in duodenal ulcer patients ranitidine 150 mg twice daily is at least four times as potent as cimetidine in the standard dosage of 200 mg three times daily and 400 mg at night in inhibiting intragastric acidity and nocturnal acid output.8 We now compare the effect of these two dose regimes on the healing of duodenal ulcer in a therapeutic trial.
Methods

PATIENTS
Adult patients with endoscopically diagnosed duodenal ulcers entered the trial; excluded were patients with previous oesophageal or gastric surgery, pyloric stenosis, gastric, pre-pyloric, pyloric canal, or post-bulbar ulcers, recent perforation, or patients on steroids and anti-inflammatory drugs. Patients with severe concurrent disease, pregnant or lactating women, and those treated with a H2-receptor antagonist within four weeks were also excluded. 
PROCEDURE
Patients were seen three to seven days after the first endoscopy and those fulfilling the criteria for entry were randomly allocated in stratified groups of 10 to treatment with either ranitidine 150 mg bd or cimetidine 200 mg tds after meals and 400 mg at night. They attended the clinic two and four weeks after entry. Antacids (Rennie tablets) were taken as needed for the relief of symptoms throughout the study. Tablet counts at each visit were used for assessment of antacid consumption. Symptoms were assessed with the aid of diary cards completed daily by each patient recording individual episodes of pain during the day and night. A second endoscopy was done within three days of completion of the fouir was no significant difference between the mean age of healers compared with non-healers (Table 2) .
PAIN RELIEF AND ANTACID CONSUMPTION
The number of episodes of pain was significantly decreased by both drugs during the first two weeks of treatment (p <0.001) (Fig. 2) , and significantly fewer antacid tablets were consumed by patients as treatment continued (Fig. 3) (p <0 01) . The reduction was similar in both groups.
UNWANTED EFFECTS
Twelve patients complained of mild side-effects (eight on ranitidine and four on cimetidine), ranging from headaches and dizziness to urinary and upper respiratory tract infections. No patients were withdrawn from the trial because of unwanted effects. Biochemical and haematological profiles showed minimal rises in creatinine (three on cimetidine, one on ranitidine) y-glutamyl transpeptidase (one in each group) and LDH (four in each group). No other changes were detected.
Discussion
This study shows that ranitidine 150 mg twice daily is as effective in the short-term healing of chronic duodenal ulcers as cimetidine 1 g daily in divided dosage. In terms of patient compliance and convenience a twice-daily regime may be preferable. The healing rate of duodenal ulcers in this trial is similar to healing rates previously reported with cimetidine9-1'i and with ranitidine 100 mg twice daily"' 18 and 150 mg twice daily.19 Variations in healing rates between centres were not significant.
Pain was diminished by both treatments and similar decreases in antacid consumption were observed. Observations in this study illustrate two points bearing on the relationship of pain, duodenitis, and healing, which are important clinically. Antacid consumption correlated reasonably well with symptoms, but neither antacid consumption nor persistence of pain could be used as predictors of lack of healing. Only five (31 %) of 16 patients experiencing three or more episodes of pain during the final week had unhealed ulcers. By contrast, of 77 patients asymptomatic during the last week, 11 (14%) had unhealed ulcers. Equal proportions (650% and 64%) of patients with or without symptoms in the final week of the trial had persistent duodenitis Investigation of the effect of more prolonged treatment on duodenitis would be interesting.
Results of this study suggest that ranitidine, like cimetidine, is effective clinically in the short-term management of duodenal ulcer. 
